Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA decision on DMD cell therapy pushed to November

25 August 2026 · By · Wire by Fusion42

Published

25 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at musculardystrophynews.com →

◆ Verified

Fusion42 · 25 August 2026 · Fusion42 review

The FDA has delayed its decision on approving Capricor Therapeutics' deramiocel cell therapy for Duchenne muscular dystrophy until November 22 to review additional long-term data from the Phase 3 HOPE-3 trial and amended statistical analyses focusing on upper arm function.

This Wire brief sits within Fusion42's coverage of Biotech, and 6 sources have reported it between 14 Aug 2026 and 25 Aug 2026.

◆ ◆ The Wire takeaway

You face a longer FDA review for DMD cell therapy approvals with new data demands raising the bar. Prepare to support or pivot around extended regulatory timelines affecting market entry in rare disease treatments.

◆ Coverage

6 sources · first reported 14 Aug 2026 · latest 25 Aug 2026

◆ Topics

Biotechfdadrug-approvalduchenne-muscular-dystrophycell-therapyclinical-trials